The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
Peter Connick(University of Cambridge), Siddharthan Chandran(Edinburgh Royal Infirmary), Michael A. Scott(Michigan State University), Madhan Kolappan(University College London), Claudia A. M. Gandini Wheeler‐Kingshott(Queen Mary University of London), Shi L Luan(University of Cambridge), Alan J. Thompson(Queen Mary University of London), Daniel J. Webber(University of Cambridge), Rebecca S. Samson(University College London), Rickie Patani(National Hospital for Neurology and Neurosurgery), Alastair Compston(University of Cambridge), Xiaoling He(Wellcome/MRC Cambridge Stem Cell Institute), Daniel J. Tozer(University of Cambridge), David L. Thomas(University College London), Kelly Barber(University College London), David H. Miller(National Hospital for Neurology and Neurosurgery), Andrew W. Michell(University of Cambridge), Daniel R. Altmann(London School of Hygiene & Tropical Medicine), Ming‐Qing Du(MRC Laboratory of Molecular Biology), Charles Crawley(Addenbrooke's Hospital), Karen Richardson(University College London)
Cited by 119
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k